Aldeyra Therapeutics Announces Presentation of Clinical Data at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

by Business Wire • 2022/04/21 • 0 Comments

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company discovering and developing innovative therapies for the treatment of immune-mediated diseases, today announced that results from the run-in cohort of the Phase 3 TRANQUILITY clinical trial of reproxalap in dry eye disease will be presented at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting. Session: Ocular Surface Disease III Session Date/Time: Satu

← Humana Announces Agreement to Divest Majority Interest in Kindred at Home Hospice and Personal Care Divisions to Clayton, Dubilier & Rice

EyeCare Partners Appoints Antonio Capone, Jr. as Chief Clinical Officer →

Post navigation